What Validus Pharmaceuticals does

Validus Pharmaceuticals LLC is a privately held U.S. specialty pharmaceutical company headquartered in Parsippany, New Jersey (90 East Halsey Road, Suite 210), founded in 2007 and operating with 11–50 employees. Rather than developing new chemical entities, the company acquires, reformulates, and markets established FDA-approved prescription products that address unmet clinical needs in specialty therapeutic areas. Its current portfolio consists of five acquired brands: Equetro (bipolar disorder), Raldesy (specialty therapeutic area), Lopressor (hypertension, beta-blocker), Lasix (loop diuretic for fluid retention/edema), and Lotensin HCT (combination antihypertensive). The company serves U.S. healthcare providers and patients through standard pharmaceutical distribution channels and a Patient Assistance Program for eligible patients.

Validus's revenue model is product commercialization of prescription pharmaceuticals, supplemented by licensing partnerships for established brands. Pricing is not publicly disclosed—consistent with prescription pharmaceutical norms where prices are negotiated through PBMs, payers, and providers—and the company operates a Comprehensive Compliance Program aligned with the PhRMA Code and HHS-OIG guidance, including formal policies on HCP detailing, samples management, and fraud-and-abuse training. Its go-to-market is enterprise field sales: healthcare-professional detailing supplemented by direct engagement with the medical community, a Patient Assistance Program for patient pull-through, and an explicit channel for business-development executives to propose licensing partnerships. The company is registered as an LLC in New Jersey, has no parent company, and shows no evidence of institutional or venture backing.

Operationally, Validus is a small, focused commercial-stage specialty pharma whose core differentiator is brand stewardship rather than R&D. Leadership includes CEO John Kinney and COO Emile Williams, the latter bringing 20+ years of commercial and finance experience from Shionogi, Novartis Pharmaceuticals, and Hoffmann-La Roche. The company markets exclusively in the United States, maintains state-level WAC pricing disclosures (Colorado, Connecticut for Raldesy), and is actively soliciting licensing partnerships, signaling a strategy of portfolio breadth through in-licensing rather than organic development or geographic expansion.

Name

Validus Pharmaceuticals

Legal name

Validus Pharmaceuticals LLC

Website

https://validuspharma.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

Validus Pharmaceuticals LLC acquires, reformulates, and markets FDA-approved prescription products in specialty therapeutic areas. The company commercializes five brands—Equetro, Raldesy, Lopressor, Lasix, and Lotensin HCT—through US pharmaceutical distribution, serving healthcare providers and patients.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Specialty Care Pharmaceuticals (HLAIAAAB)

akta.pro secondary industries

Cardiology & Vascular Specialty Pharmaceuticals (HLAIACAG), Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Specialty pharmaceuticals
• Prescription drug marketing
• Product reformulation
• FDA-approved medications
• Pharmaceutical licensing

Headquarters

HQ city

Parsippany

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Marketing or Sales, Supply Chain, Personnel, Operations, Technology or R&D, Others

Revenue model

1. Product Commercialization: Validus generates revenue through the acquisition, reformulation, and commercialization of FDA-approved prescription products in specialty therapeutic areas. The company also derives value through licensing partnerships where they bring established brands to market.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels2 records

Core offering

Validus Pharmaceuticals acquires, reformulates, and markets FDA-approved prescription products in specialty therapeutic areas. Its portfolio includes Equetro for bipolar disorder, Raldesy (specialty therapeutic area), Lopressor (hypertension), Lasix (fluid retention/edema), and Lotensin HCT (combination antihypertensive). The company also pursues licensing partnerships with business development executives to extend the value of established brands.

Product overview

Validus Pharmaceuticals LLC is a specialty pharmaceutical company focused on acquiring, reformulating, and marketing FDA-approved prescription products that address unmet clinical needs. The company's portfolio consists of five acquired brands spanning multiple therapeutic areas: Equetro (bipolar disorder treatment), Raldesy (specialty therapeutic area), Lopressor (cardiovascular/hypertension), Lasix (diuretic for fluid retention), and Lotensin HCT (combination antihypertensive). Rather than developing new products, Validus acquires established products and commercializes them through its distribution and partnership network.

Differentiator

Problem solved

Functional benefit

Brands

• Equetro: Prescription pharmaceutical product marketed by Validus Pharmaceuticals
• Raldesy
• Lopressor
• Lasix
• Lotensin HCT

Products and services

• Equetro A prescription medication for the treatment of bipolar disorder, acquired and commercialized by Validus Pharmaceuticals.
• Raldesy A prescription pharmaceutical product acquired and marketed by Validus Pharmaceuticals in specialty therapeutic areas.
• Lopressor A beta-blocker medication for the treatment of hypertension, acquired and commercialized by Validus Pharmaceuticals.
• Lasix A loop diuretic medication for the treatment of fluid retention and edema, acquired and commercialized by Validus Pharmaceuticals.
• Lotensin HCT A combination medication for the treatment of hypertension, acquired and commercialized by Validus Pharmaceuticals.

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Licensing Partnership CandidatescoreChannel Partner/ Reseller/ DistributorValidus Pharmaceuticals welcomes inquiries from business development executives interested in licensing partnerships. The company focuses on deriving further value from established brands through partnerships. The company is open to acquiring and commercializing prescription products that satisfy unmet clinical needs in specialty therapeutic areas.

Recent moves5 records

Expansion highlights4 records

Direct peers

• Aurobindo Pharma: Vertically integrated pharmaceutical company with significant branded and generic prescription product offerings across cardiovascular and CNS. Comparable to Validus in commercial portfolio strategy, though much larger in manufacturing and scale.
• Upsher-Smith Laboratories: Private specialty pharmaceutical company marketing established branded prescription products, including cardiovascular and CNS franchises. Comparable to Validus in business model (acquire and commercialize legacy brands) and approximate scale.
• Amneal Pharmaceuticals: Specialty and generic pharmaceutical company focused on affordable prescription medicines across therapeutic categories. Comparable to Validus in operating a multi-brand prescription portfolio with both legacy and specialty assets.
• Apotex: Privately held pharmaceutical company developing, manufacturing, and marketing a broad range of generic and specialty prescription medicines. Comparable to Validus in private ownership and multi-therapeutic prescription portfolio approach.
• Hikma Pharmaceuticals: Specialty and generic pharmaceutical company marketing branded and generic prescription products, including cardiovascular and CNS franchises. Directly comparable to Validus in commercial model and therapeutic mix.
• ANI Pharmaceuticals: Specialty pharma focused on acquiring, developing, and commercializing branded and generic prescription products in niche therapeutic areas. Closely comparable to Validus in scale, acquisition-led strategy, and focus on established molecules.
• Mallinckrodt Pharmaceuticals: Specialty pharma company with a portfolio of branded and generic prescription products across multiple therapeutic areas. Comparable in the brand-acquisition and lifecycle-extension approach, though larger in scale.
• Endo Pharmaceuticals: Specialty pharmaceutical company that acquires, develops, and markets branded prescription products across multiple therapeutic areas. Directly comparable to Validus in its brand-acquisition and lifecycle-management model, including exposure to mature cardiovascular and CNS franchises.
• Prasco Laboratories: Privately held specialty pharmaceutical company that markets authorized generics and branded prescription products. Comparable to Validus in leveraging established molecules and brand recognition in commercial markets.

Broad incumbents

• Bausch Health: Large diversified specialty pharmaceutical company with a broad branded prescription portfolio across multiple therapeutic areas. Comparable to Validus in brand-acquisition strategy, but operates at significantly greater scale across many categories.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/validus-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Validus Pharmaceuticals